Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Sr Director Finance/Controller | July 07, 2022 | July 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date July 07, 2022 · Filed July 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2029-09-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-07 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: One quarter of the options vested on September 1, 2020 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2030-03-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: One quarter of the options vested on March 17, 2021 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2031-03-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: One quarter of the options vested on March 15, 2022 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2032-03-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: One quarter of the options will vest on March 10, 2023 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment. |
Filing footnotes · ownership attribution and instrument terms
F1: One quarter of the options vested on September 1, 2020 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.
F2: One quarter of the options vested on March 17, 2021 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.
F3: One quarter of the options vested on March 15, 2022 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.
F4: One quarter of the options will vest on March 10, 2023 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2021 Filed Apr 2, 2021 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001493152-21-007795 · ownership.xml · derivative · entry 4 Hernandez Alexandra · CIK 0001841756 · Sr Director Finance/Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Shares · 6,000 shares Expires 2030-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One quarter of the options vested on March 17, 2021 and the balance vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | SaleCommon Shares, no par value | 6,000 | $2.23 | $13,380.00 |
DisclosureSEC source: 0001493152-21-007795 · ownership.xml · nonDerivative · entry 2 Hernandez Alexandra · CIK 0001841756 · Sr Director Finance/Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 6,000 | $0.69 | $4,151.40 |
DisclosureSEC source: 0001493152-21-007795 · ownership.xml · nonDerivative · entry 1 Hernandez Alexandra · CIK 0001841756 · Sr Director Finance/Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Apr 2, 2021 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 42,700 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001493152-21-007795 · ownership.xml · derivative · entry 3 Hernandez Alexandra · CIK 0001841756 · Sr Director Finance/Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,700 Underlying: Common Shares · 42,700 shares Expires 2031-03-15 F1 · derivative.exercise_date: One quarter of the options vest on March 15, 2022 and the balance vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.